 |
 |
J Neur N'surg Psych 1999;67:(advertisement): This ad implies that the catechol-0-methyl transferase (COMT) inhibitor entacapone (Comtess) is now approved for treatment of PD in the UK. Like tolcapone (Tasmar), entacapone prolongs the bioavailability of levodopa by slowing its breakdown, thereby permitting lower dosage of levodopa for equivalent results; not as potent as tolcapone, but requires no blood tests. No word yet on introduction (as Comtan) in the U.S. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013